Patent · US Active

Anti-GARP protein

US11230603B2 · kind B2 · utility

0Cited by

5References

15Claims

0Family size

Assignees

LUDWIG INSTITUTE FOR CANCER RESEARCH LTD · GB
UNIVERSITÉ CATHOLIQUE DE LOUVAIN · BE
argenx BVBA · BE

Inventors

Sophie Lucas · Brussels, BE
Pierre Coulie · Brussels, BE
Julia Cuende Villasur · Louvain-la-Neuve, BE
Laure Dumoutier · Brussels, BE
Jean-Christophe Renauld · Bouillon, BE
Sebastian Van Der Woning · Deinze, BE
Michael John Scott Saunders · Wondelgem, BE
Hans De Haard · Oudelande, NL
Gitte De Boeck · Malderen, BE

Key dates

Filing date	Feb 14, 2020
Grant date	Jan 25, 2022
Priority date	—
Expiry date	Feb 14, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a protein binding to GARP in the presence of TGF-β and uses thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.